Skip to main content
Donate

FAST Research Series

The following are published posts in a series that summarizes  lectures presented on Friday December 4th, 2015, the first day of the 2015 FAST Global Summit. This series will focused on research, pre-clinical, and future clinical trials.  Be sure to join our mailing list so that you don't miss any of these exciting articles! pic  

Summary of FAST 2015 Research Lectures

A great summary, revisiting some simple facts to refresh your memory to help put the subsequent posts in context. This also is a fantastic resource for explaining Angelman Syndrome to someone who has never heard of it before. Read here...  
  Ovid  

Ovid Therapeutics – OV101 as a potential therapeutic

Ovid Therapeutics is currently assessing the development of OV-101 for the treatment of Angelman Syndrome. Ovid will be working to select measures that reflect the burden of the syndrome on the patients and their families. This is likely to include sleep, motor, and behavioral measurements.  Read more here...  
  32610318_m

Gene therapy for the treatment of Angelman Syndrome: Future clinical trials

Agilis Biotherapeutics recently announced that they have  granted an Orphan Drug Designation status by the U.S. FDA for the indication of Angelman syndrome. This is a first for Angelman Syndrome.  This post explains more about gene therapy and the approach that Agilis are taking. Read more...  
Dave-with-bad-haircut  

The FIRE team of FAST turns on Ube3a in mice with Angelman Syndrome

FIRE team member Dr David Segal (pictured with Grad student Barbara Bailus)  talks about the recently published paper "Protein Delivery of an Artificial Transcription Factor Restores Widespread Ube3a Expression in an Angelman Syndrome Mouse Brain". The future gets even more promising with Zinc Finger technology.  Read more...
DisruptiveNutrition

Medical foods as an effective approach to management of Angelman Syndrome

More promise in 2016...another clinical trial on its way for Angelman Syndrome using Disruptive Nutrition -- based on a FAST funded pre-clinical trial.  Read more...

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.